Cadila Healthcare has received tentative approval to market Tadalafil tablets which are available in strengths of USP, 2.5 mg, 5 mg, 10 mg and 20 mg, from the USFDA.

The drug which has received approval is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). Further, it will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.

Read EquityPandit’s Technical Analysis of Indian Stock Market